Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-4,page-paged-4,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

CLIENT NEWS

 

 

  • InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
    31 March 2022
    www.inflarx.de
  • Data on the antimicrobial activity of XF-73 against bacteria within biofilms to be presented at prestigious 2022 ECCMID Congress
    31 March 2022
    www.destinypharma.com
  • HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors
    30 March 2022
    www.heparegenix.com/
  • Adocia strengthens its cash position by 19 million euros following a real estate transaction
    28 March 2022
    www.adocia.com
  • Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron
    28 March 2022
    www.atriva-therapeutics.com
  • InflaRx Reports Full Year 2021 Financial and Operating Results
    24 March 2022
    www.inflarx.de
  • Heidelberg Pharma Announces Financial Figures for Fiscal Year 2021 and Provides Business Update
    24 March 2022
    www.heidelberg-pharma.com
  • Atriva Therapeutics announces changes in its Management Team
    22 March 2022
    www.atriva-therapeutics.com
  • InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
    17 March 2022
    www.inflarx.de
  • Abivax reports 2021 financial results and operations update
    16 March 2022
    www.abivax.com